Pergolida [Inn-Spanish]
Pergolida [Inn-Spanish] Brand names, Pergolida [Inn-Spanish] Analogs
Pergolida [Inn-Spanish] Brand Names Mixture
- No information avaliable
Pergolida [Inn-Spanish] Chemical_Formula
C19H26N2S
Pergolida [Inn-Spanish] RX_link
http://www.rxlist.com/cgi/generic2/pergol.htm
Pergolida [Inn-Spanish] fda sheet
Pergolida [Inn-Spanish] msds (material safety sheet)
Pergolida [Inn-Spanish] Synthesis Reference
No information avaliable
Pergolida [Inn-Spanish] Molecular Weight
314.489 g/mol
Pergolida [Inn-Spanish] Melting Point
207.5 oC
Pergolida [Inn-Spanish] H2O Solubility
No information avaliable
Pergolida [Inn-Spanish] State
Solid
Pergolida [Inn-Spanish] LogP
4.02
Pergolida [Inn-Spanish] Dosage Forms
Tablet
Pergolida [Inn-Spanish] Indication
Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.
Pergolida [Inn-Spanish] Pharmacology
Pergolide is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Pergolide is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Pergolide mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.
Pergolida [Inn-Spanish] Absorption
Significant amount may be absorbed (evidence on bioavailability still lacking).
Pergolida [Inn-Spanish] side effects and Toxicity
Oral, rat LD50: 15 mg/kg. Symptoms of overdose include nausea, vomiting, convulsions, decreased blood pressure, and CNS stimulation.
Pergolida [Inn-Spanish] Patient Information
Pergolida [Inn-Spanish] Organisms Affected
Humans and other mammals
![Pergolida_[Inn-Spanish]](/images/rx/APRD00663.gif)
